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Abstract
Background/objectives A better understanding of adipose tissue biology is crucial to tackle insulin resistance and eventually
coronary heart disease and diabetes, leading causes of morbidity and mortality worldwide. GALNT2, a GalNAc-transferase,
positively modulates insulin signaling in human liver cells by down-regulating ENPP1, an insulin signaling inhibitor.
GALNT2 expression is increased in adipose tissue of obese as compared to that of non-obese individuals. Whether this
association is secondary to a GALNT2-insulin sensitizing effect exerted also in adipocytes is unknown. We then investigated
in mouse 3T3-L1 adipocytes the GALNT2 effect on adipogenesis, insulin signaling and expression levels of both Enpp1 and
72 adipogenesis-related genes.
Methods Stable over-expressing GALNT2 and GFP preadipocytes (T0) were generated. Adipogenesis was induced with (R
+) or without (R−) rosiglitazone and investigated after 15 days (T15). Lipid accumulation (by Oil Red-O staining) and
intracellular triglycerides (by fluorimetric assay) were measured. Lipid droplets (LD) measures were analyzed at confocal
microscope. Gene expression was assessed by RT-PCR and insulin-induced insulin receptor (IR), IRS1, JNK and AKT
phosphorylation by Western blot.
Results Lipid accumulation, triglycerides and LD measures progressively increased from T0 to T15R- and furthermore to T15R+.
Such increases were significantly higher in GALNT2 than in GFP cells so that, as compared to T15R+GFP, T15R- GALNT2 cells
showed similar (intracellular lipid and triglycerides accumulation) or even higher (LD measures, p < 0.01) values. In GALNT2
preadipocytes, insulin-induced IR, IRS1 and AKT activation was higher than that in GFP cells. GALNT2 effect was totally
abolished during adipocyte maturation and completely reversed at late stage maturation. Such GALNT2 effect trajectory was
paralleled by coordinated changes in the expression of Enpp1 and adipocyte-maturation key genes.
Conclusions GALNT2 is a novel modulator of adipogenesis and related cellular phenotypes, thus becoming a potential
target for tackling the obesity epidemics and its devastating sequelae.
Introduction
Obesity and adipose tissue dysfunction are major movers of
insulin resistance, thus predisposing to leading causes of
morbidity and mortality [1], such as coronary heart disease
and type 2 diabetes [2]. A better understanding of the
mechanisms controlling adipogenesis is therefore of crucial
importance.
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Insulin stimulates lipid storage in adipocytes [3]. So, it is
not surprising that insulin sensitivity prospectively predicts
weight gain increase [4]. Further confirming that insulin
sensitivity positively controls body weight is the common
observation that thiazolidinediones—insulin sensitizing
molecules used as anti-hyperglycemic drugs in type 2 dia-
betes—increase body mass index (BMI) [5].
GALNT2, a GalNAc-transferase [6] involved in O-linked
glycosylation [7], modulates the risk of atherogenic dyslipi-
demia [8–11], a specific hallmark of insulin resistance and
acts as a positive modulator of insulin signaling in human
liver cells, by down-regulating ENPP1, an inhibitor of insulin
receptor (IR) [12]. Interestingly, GALNT2 expression in
subcutaneous adipose tissue is increased in obese, insulin
resistant individuals as compared to their non-obese coun-
terparts [13]. Whether this association underlies a cause-effect
relationship, with GALNT2 firstly predisposing to weight
gain by exerting a positive modulation on adipose tissue
insulin signaling and eventually concurring to develop obesity
and the inevitably related insulin resistance, is a reasonable
possibility that has never been addressed. In order to get
deeper insights about this hypothesis, we investigated in
cultured mouse adipocytes the effect of GALNT2 on adipo-
genesis, lipid accumulation and insulin signaling.
Materials and methods
Cell culture
Both mycoplasma-free 3T3-L1 murine fibroblast (Addex-
Bio), and 293T cells (ATCC) were routinely cultured in
high-glucose Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma-Aldrich) supplemented with 10% fetal
bovine serum (FBS) (EuroClone) and maintained at 37 °C
in a humidified atmosphere with 5% CO2.
Recombinant Lentivirus production and
transduction
Human ORF GALNT2 cloned into pLX304 vector under
CMV promoter (pLXGALNT2) and both dR8.91 (Packa-
ging plasmid) and VSV-G (Envelope plasmid), used for
lentiviral production, were purchased from Harvard Medical
School Facilities. Plasmid pRRL-PGK-GFP was kindly
provided by F. Carlotti (Nice, FR) [14].
Lentiviral particles were generated by co-transfecting either
pLXGALNT2 or pRRL-PGK-GFP with both dR8.91 and
VSV-G plasmids in 293T cells by calcium phosphate method
[15]. Cells were then maintained in DMEM supplemented
with 30% FBS for 18 h and lentiviral particles harvested, fil-
tered through 0.45 µm filter and stored at −80 °C until used.
In order to obtain 3T3-L1 cell lines over-expressing either
GFP (GFP cells) or GALNT2 (GALNT2 cells), both viral
supernatants were added to fresh medium supplemented with
8 µg/ml Polybrene (Sigma-Aldrich) and 3T3-L1 cells incu-
bated overnight. After 24 h, the medium was replaced with
fresh DMEM plus 10% FBS and, then, changed every 2 days.
GALNT2 transduced cells were further selected by adding
5 µg/ml of blasticidin (Thermo Fisher Scientific). GFP cells
were used as control in all experiments.
3T3-L1 adipocytes differentiation
Cells were seeded either in 6-well-plates (Sigma-Aldrich) or
in 18 × 18 mm sterile imaging glasses, at ~8 × 103cell/cm2
cell density and grown in DMEM plus 10% FBS for 4 days
in order to obtain 100% confluence (T0 GFP and T0
GALNT2 cells). Cell differentiation was induced, by using
DMEM plus 1 µM dexamethasone (Calbiochem), 0.5 mM
1-methyl-3-isobutylxanthine (Calbiochem), 5 µg/ml human
recombinant insulin (Gibco) and either with (R+) or with-
out (R−) 2 µM rosiglitazone (Cayman Chemical). After
48 h, R+ and R− differentiation mediums were replaced
with 10% FBS supplemented DMEM plus either 5 µg/ml
insulin, with a biweekly medium replacement until day 15
(T15 GFP and T15 GALNT2 cells).
Oil Red O staining and lipid quantification
Oil Red-O (ORO) staining was performed in T0, T15R− and
T15R+cells as it follows. Briefly, cells were fixed with 10%
formalin for at least 1 h, rinsed with 60% isopropyl alcohol
and, after complete drying, treated with ORO for 10 min.
Cells were then washed 4 times with deionized H2O and
dried. Embedded ORO, an inferred measures of intracellular
lipids, was eluted, by adding 100% isopropyl alcohol for
10 min, and quantified at 500 nm by Synergy-HT spectro-
photometer (Bio-Tek). The resulting optical densities (OD)
were expressed as percentage on either T0 GFP or T0
GALNT2 cells, respectively.
Intracellular triglycerides levels were measured in T0,
T15R− and T15R+cells by means of the fluorimetric enzy-
matic Adipogenesis Assay Kit according to manufacturer’s
instruction (Sigma-Aldrich). The resulting fluorimetric
intensities were measured at 587 nm by Synergy-HT
Fluorimeter (Bio-Tek), plotted versus a triglycerides stan-
dard curve and expressed as nmol/5000 cells.
Adipo Red staining
T0, T15R− and T15R+cells were rinsed twice with
phosphate-buffer saline (PBS), fixed with 4% paraf-
ormaldehyde for 15 min and then incubated with Adipo Red
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stain (Lonza) for 10 min. Next, cells were washed with PBS
and adipocyte lipid droplets (LD) imaged.
Imaging
ORO-stained cells were imaged in bright field by means of
an inverted microscope (Axiovert 2 M, Zeiss) at ×5 mag-
nification (Zeiss FLUAR 5 × /0.25na objective).
Images’ acquisition of Adipo Red-stained adipocytes
was performed by using a TCS SP8 confocal microscope
(Leica) at ×40 magnification (HC PL APO CS2 40 × /1.30
OIL Leica objective). At least 30 independent micrographs
were acquired for each experimental condition. LD mor-
phology was then analyzed by using Cell Profiler software.
Briefly, images were segmented to identify lipids as discrete
“objects” and then area and Feret’s diameter (which account
for LD size, in terms of diameter for rounded objects or
major axis for irregular objects) were measured.
Western blot analysis
Cell lysates were separated by SDS-PAGE and transferred to
nitrocellulose membrane Trans-Blot Turbo Transfer pack
(Biorad). Blots were probed with specific antibodies, includ-
ing anti-GALNT2 (ab97741, Abcam), anti β-Actin (sc-47778,
Santa Cruz Biotechnology), anti-IR β-subunit (sc-711, Santa
Cruz Biotechnology), anti-Phospho-IRS1Tyr895 (3070, Cell
Signaling), anti-IRS1 (2382, Cell Signaling), anti-phospho-
JNK1/JNK2Thr183/Tyr185 (700031 Thermo Fisher Scientific),
anti-JNK (9252, Cell Signaling), anti-Phospho-AKTSer473
(9271, Cell Signaling) and anti-AKT (9272, Cell Signaling).
Immune-complexes were then detected with the Super-
SignalTM West Pico (Thermo Fisher Scientific). Gel images
were acquired by using Molecular Imager ChemiDoc XRS
(Biorad) and band intensities quantified by Kodak Molecular
Imaging Software 4.0 as OD values.
Insulin signaling
Cells were starved for 18 h with DMEM plus 0.5% FBS,
stimulated with 10−7 M insulin for 5 min at 37 °C, and then
washed with PBS and lysed. To evaluate IR β-subunit auto-
phosphorylation, 300 µg of total lysate were immune-
precipitated with anti-PY99 antibody (sc-7020, Santa Cruz
Biotechnology) and analyzed by Western blot as described
above. To evaluate IRS1, JNK and AKT activation, 50 µg
of total lysate were subjected to SDS-Page and IRS1Tyr895,
JNK1/JNK2Thr183/Tyr185 and AKTSer473 phosphorylation
evaluated by western blot (see above). IRS1Tyr895, JNK1/
JNK2Thr183/Tyr185 and AKTSer473 phosphorylation levels
were normalized against IRS1, JNK and AKT content. All
data were calculated as percentage of insulin-stimulated
GFP adipocytes and expressed as means ± SE.
RNA extraction, cDNA synthesis, and gene
expression analysis
Total RNA was isolated from mature adipocytes by using
RNeasy Mini kit (Qiagen). cDNA was generated by reverse
transcription with iScript™ Reverse Transcription Super-
mix for RT-qPCR (Biorad) according to the manufacturer’s
instructions and used as template for subsequent analyses.
Expression levels of 72 adipogenesis-related genes (Gene
Target List can be found in Supplementary Information 1)
were assessed by means of pre-designed Adipogenesis
M384 SYBR green panels (Biorad), on ABI-PRISM 7900
(Applied Biosystems). Among 8 reference genes (see
Supplementary Information 1), β-actin, Gusb and
Hsp90ab1 were chosen as those showing the best control
gene-stability measured as indicated by M value (i.e., M <
0.5) across samples [16]. PrimeTime qPCR Probe Assays
(Integrated DNA Technologies) were used to measure
expression levels of Ennp1 (Mm.PT.58.7142160), mGalnt2
(Mm.PT.58.5475747) and hGALNT2 (Hs.PT.58.3633908)
on ABI-PRISM 7900 (Applied Biosystems). Gene expres-
sion levels were reported as ΔΔCq, calculated as relative
gene quantity normalized to the geometric mean of refer-
ence genes (PrimePCR™ Analysis Software, Biorad).
Statistical analyses
Each experiment, for each condition, has been carried out at
least 3 times in duplicate. Differences between mean values
were evaluated by Student’s t-test; a two sided p-values <
0.05 were considered for statistical significance. Data are
presented as means ± SE. Analyses were performed by
using SAS Software, Release 9.4 (SAS Institute, Cary,
NC, USA).
Results
Over-expression of GALNT2 in 3T3-L1 cells
Firstly, 3T3-L1 cell lines expressing either GFP (GFP cells)
or GALNT2 (GALNT2 cells) were created as described in
methods. As compared to GFP cells, a clear band repre-
senting human GALNT2 was detectable at ~60 KDa in
GALNT2 cells at both T0 (preadipocytes, Fig. 1a) and T15
(mature adipocytes, Fig. 1b).
Role of GALNT2 on mature adipocyte proportion
and lipid accumulation
Adipogenesis was then induced for 15 days in T0 GFP and
T0 GALNT2 cells. Figure 2a shows representative micro-
graphs of undifferentiated T0 cells (images 1 and 4) and
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mature adipocytes, either T15R− (images 2 and 5) or T15R
+(images 3 and 6). In GFP cells, the apparent proportion of
mature adipocytes progressively increased from T0 to T15R-
and to T15R+ (images 1–3). A similar, though stronger,
increase was observed in GALNT2 cells (images 4–6). In
fact, as compared to GFP cells, the proportion of mature
adipocytes appeared to be higher in their GALNT2 coun-
terparts (image 5 vs. 2 and image 6 vs. 3). In addition, the
proportion of mature adipocytes in T15R−GALNT2 cells
looked quite similar to that in T15R+GFP cells (image 5 vs.
3), as if the magnitude of GALNT2 effect were similar to
that of rosiglitazone.
Figure 2b (left side) shows that, as compared to T0 GFP
cells, lipid content was significantly increased in T15R− (1.7
fold-increase) and even more in T15R+ (2.2 fold-increase)
GFP cells. A similar, though stronger, trend was observed
also in GALNT2 cells (Fig. 2b, right side), with differences
vs. their T15 GFP counterparts becoming significant (p=
0.01) for the T15R+condition (Fig. 2b, black bars). It is
worth noticing that lipid accumulation in T15R−GALNT2
cells was virtually identical to that in T15R+GFP cells (Fig.
2b, right side white bar vs. left side black bar).
Very similar results were obtained when intracellular
triglycerides levels were measured. In fact, as compared to
T0 GFP cells (Fig. 2c, left side), triglycerides were sig-
nificantly increased in T15R− (3.5-fold-increase) and even
more in T15R+ (4.2-fold-increase) GFP cells. An even
stronger trend was observed in GALNT2 cells (Fig. 2c,
right side), with differences vs. their T15 GFP counterparts
being significant for both T15R− (p= 0.019) and T15R+
(p= 0.034) conditions (Fig. 2c, white bars and black bars,
respectively). Also in this case, it is worth noticing that
triglycerides accumulation in T15R−GALNT2 cells was
virtually identical to that in T15R+GFP cells (Fig. 2c, right
side white bar vs. left side black bar). Then, for both lipid
accumulation and triglycerides content, these results parallel
those referring to the proportion of mature adipocytes and
give further support to the concept that the magnitude of
GALNT2 stimulatory effect on adipogenesis is similar to
that of rosiglitazone.
Fig. 1 Over-expression of GALNT2 in 3T3-L1 cells. 3T3-L1 cells
were transduced with either pLX304_GALNT2 or pLV-CMV-GFP as
described in Materials and Methods. GALNT2 expression was eval-
uated at T0 (a) and T15 (b) by western blot. In brief, equal amounts of
protein from cell lysates were separated by SDS-PAGE and probed
with GALNT2 (upper blot) or β-actin (lower blot) specific antibodies
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Role of GALNT2 on droplet morphology in mature
adipocytes
Representative LD images in mature adipocytes are shown
in Fig. 3a. In both cell lines, rosiglitazone treatment
increased LD size and roundness (Fig. 3a, panel 2 vs. 1 and
panel 4 vs. 3). Notably, LD size in T15R−GALNT2 cells
looked similar if not larger than that in T15R+GFP cells
(Fig. 3a, panel 3 vs. 2), again pointing to an effect of
GALNT2 over-expression of a similar magnitude of
rosiglitazone.
LD morphology was measured by means of 2 shape
descriptors (Figs. 3b, c), including area and size. As com-
pared to their T15R- counterparts, LD area was significantly
increased in both T15R+GFP and GALNT2 cells (Fig. 3b),
while LD size was significantly higher only in T15R+GFP
cells, with only mild, non-significant increase showed by
GALNT2 cells (Fig. 3c). LD area and size in GALNT2 cells
were significantly increased as compared to their GFP
counterparts, both without and with rosiglitazone treatment
(Figs. 3b, c). Notably, LD area and size in T15R-GALNT2
cells were significantly greater than those of T15R+GFP
cells (Figs. 3b, c), thus indicating that the effect of
GALNT2 over-expression in modulating also this addi-
tional adipogenesis-related phenotype is at least similar if
not larger than that of rosiglitazone.
Taken altogether, our data indicate that GALNT2 has a
positive role on 3T3-L1 differentiation, lipid accumulation
and LD morphology whose magnitude resembles very
much that of rosiglitazone.
Role of GALNT2 on insulin signaling
Given that adipocyte maturation is under the control of
insulin signaling, time course experiments of insulin-
induced IR, IRS1, AKT and JNK1/JNK2 phosphorylation
were carried out, so to get deeper insights on the molecular
mechanisms underlying GALNT2 effect on adipocyte
enlargement. In both GFP and GALNT2 cells, a clear
insulin stimulation of IR β-subunit auto-phosphorylation,
IRS1Tyr895 and AKTSer473 phosphorylation (Figs. 4a–c,
respectively) was observed at T0, T9 and T15. In GALNT2
preadipocytes, insulin-induced IR was significantly higher
than that observed in GFP cells (Fig. 4a, T0). This
GALNT2 stimulatory effect was no longer observed during
adipocyte maturation (Fig. 4a, T9), and totally reversed at
late stage maturation, where GALNT2 enlarged adipocytes
showed a significantly reduced insulin-induced IR phos-
phorylation (Fig. 4a, T15). A virtually identical trend of
GALNT2 effect was observed for both insulin-induced
IRS1 and AKT activation (Figs. 4b, c), though statistical
significance for IRS1 stimulation in preadipocytes (T0) was
not reached.
Finally, as compared to their GFP counterparts, insulin-
induced JNK1/JNK2Thr183/Tyr185 was similar in GALNT2
Fig. 2 Role of GALNT2 on adipocyte proportion and lipid accumu-
lation. GFP and GALNT2 cells were differentiated into adipocytes
either with (R+) or without (R−) rosiglitazone. a shows Oil-red-O
(ORO) staining (see Material and Methods) of lipids in representative
5 × (gray-scale) microscopy images of cells at T0 and T15. Scale bar=
500 µm. b shows quantitative analysis of eluted ORO (see Material
and Methods) at T0 and T15. Bars represent eluted-ORO optical density
(OD) from both T15R− and T15R+ (white and black bars, respectively)
cells, expressed as percentage of that from T0 (gray bars) cells. c shows
quantitative analyses of extracted triglycerides (see Material and
Methods) at T0 and T15. Bars represent intracellular triglycerides from
T0 (gray bars) and both T15R− and T15R+ (white and black bars,
respectively) expressed as nmol/5000 cells. Data are means ± SE of 6
independent experiments. *2 sided p < 0.05 by Student’s t-test
Fig. 3 Effect of GALNT2 on lipid droplet morphology in mature
adipocytes. GFP and GALNT2 cells were differentiated into adipo-
cytes with (R+) or without (R−) rosiglitazone and stained with Adipo
Red as described in Material and Methods. Panel a shows repre-
sentative details of Adipo Red-stained LD from ×40 confocal micro-
scopy images of T15R− and T15R+cells. Scale bar= 25 µm. b, c show
quantitative analyses of LD area and size, respectively. Bars represent
micron-scale measurements of LD area (b) and size (c) from both
T15R− and T15R+ (white and black bars, respectively) cells. Data are
means ± SE of LD measurements from at least 30 fields of view from 2
independent experiments. *2 sided p < 1 × 10−5 by Student’s t-test
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cells at T0 (109% ± 9 SE of GFP stimulated cells, n= 3), T9
(99% ± 11 SE of GFP stimulated cells, n= 3) and T15 (94%
± 8.3 SE of GFP stimulated cells, n= 3). Representative
experiments at each time point are shown in Supplementary
Information 2. These data suggest that GALNT2 effect on
adipogenesis is not modulated by JNK signaling.
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In all, data in preadipocytes are definitively consistent
with the reported positive role of GALNT2 on insulin
sensitivity in other cell types [12], which in turn stimulates
adipocyte maturation and eventually adipocyte enlargement
[17]. Conversely, the reduced insulin signaling in mature
GALNT2 adipocytes is fully compatible with the well-
known decreased insulin sensitivity characterizing enlarged
adipocytes [18, 19].
Role of GALNT2 on the expression of ENPP1 and
genes related to adipogenesis
Firstly, the expression of Enpp1, a negative modulator of
insulin signaling whose expression in liver cells is
decreased by GALNT2 [12], was evaluated. In fact, as
compared to GFP counterparts, in GALNT2 cells Enpp1
expression was similar at T0 (1.15 fold, n= 3) and was
progressively down-regulated at T9 (1.6 fold-decrease, n=
3) and even more strikingly at T15 (6.9-fold-decrease, n=
3 ). Of note, such Enpp1 down-regulation was not paralleled
by changes in Galnt2 expression in T9 and T15 as compared
to T0 (fold-change at both time points ranging from −1.4 to
1.2, n= 3). Finally, also no changes were observed during
adipogenesis in the expression of hGALNT2 in transfected
cells (data not shown, n= 3).
Then, expression levels of 72 adipogenesis-related genes
were measured during adipocyte maturation, at T0 (Fig. 5a),
T9 (Fig. 5b) and T15 (Fig. 5c). At each time point, several
genes were at least 2-fold changed in GALNT2 cells as
compared to their GFP counterparts. In details, 6 genes
were either increased (Hes1) or decreased (Agt, Foxc2,
Klf15, Ucp1, Wnt5a) at T0, 13 were either increased (Adig,
Adipoq, Retn, Bmp4, Hes1) or decreased (Agt, Cebpb,
Gata2, Lipe, Rxra, Tsc22d3, Ucp1, Wnt5a) at T9, and 21
were either increased (Adig, Adipoq, Adrb2, Cebpa, Fabp4,
Nr1h3, Retn, Wnt5b) or decreased (Agt, Egr2, Fgf2, Gata2,
Insr, Lipe, Runx1t1, Rxra, Slc2a4, Tsc22d3, Ucp1, Wnt1,
Wnt5a) at T15. Of these 21 genes, 3 were already
downregulated at T0 and maintained as such also at T9 (Agt,
Ucp1, Wnt5a), while 7 were either upregulated (Adig,
Adipoq, Retn) or downregulated (Gata2, Lipe, Rxra,
Tsc22d3) only starting from T9.
In all, these results strongly suggest that GALNT2
induces a coordinated and time-dependent change in the
expression of adipocyte maturation key genes which is
likely to have played a role on the different adipogenesis
observed in GALNT2 as compared to GFP cells.
Discussion
Our previous work pointed GALNT2 as a positive mod-
ulator of insulin signaling in human liver cells [12, 18–21].
Based on the notion that GALNT2 expression is increased in
subcutaneous adipose tissue of obese individuals [13] and
that insulin signaling stimulates adipocytes differentiation
[3], we have now tested the hypothesis that GALNT2 exerts
a stimulatory role on adipogenesis.
As a matter of fact, our data clearly show that in 3T3-L1
mouse cells GALNT2 stimulates adipogenesis as indicated
by increased proportion of mature adipocytes, intracellular
lipids, including triglycerides, and lipid droplets dimension.
Of note, the magnitude of GALNT2 stimulatory effect on
adipogenesis was relevant, being superimposable to that
exerted by rosiglitazone [5], a potent stimulator of adipo-
genesis [22] known to cause weight gain in patients with
type 2 diabetes [5].
GALNT2 stimulatory effect on adipogenesis was paral-
leled by improved insulin signaling in preadipocytes. This
effect was abolished during adipocyte maturation and
completely reversed at late stage maturation as a possible
consequence of adipocytes enlargement [18–21]. These data
suggest that if adipocytes are pushed to maturation from the
very early stages, the whole adipogenesis until late stage
and ultimate adipocytes enlargement is heavily
compromised.
During adipogenesis GALNT2 cells were also char-
acterized by Enpp1 down-regulation, a negative modulator
of insulin signaling [23–25], thus confirming previous data
we reported in human cultured liver cells over-expressing
GALNT2 [12]. Taken together these two piece of data
strongly suggest that during cell differentiation GALNT2
down-regulated Enpp1, so increasing insulin signaling and
stimulating adipogenesis [12, 26]; however, once adipo-
genesis was established, the positive GALNT2 effect on
insulin signaling, was eventually overwhelmed by the
opposite deleterious effect on the same insulin signaling
ineludibly exerted by adipocytes enlarging [18–21]. This
latter phenomenon, which is likely part of the adipocyte
homeostatic response aimed at impeding further enlarge-
ment under conditions of continuous insulin stimulation
Fig. 4 Role of GALNT2 on insulin signaling. GFP and GALNT2 cells
were stimulated with 10−7 M insulin and then IR β-subunit (a),
IRS1Tyr895 (b) and AKTSer473 (c) phosphorylation were evaluated by
Western blot analyses as described in Materials and Methods. a Bars
represent quantitative analysis of IR β-subunit phosphorylation
expressed as percentage of that observed in insulin-stimulated GFP
cells (white bars) at T0 (n= 3), T9 (n= 3), and T15 (n= 6). b Bars
represent quantitative analyses of insulin-induced IRS1Tyr895 phos-
phorylation/IRS1 OD ratio expressed as percentage of that observed in
insulin-stimulated GFP cells (white bars) at each time points (T0, T9
and T15, n= 3 at all time points). c Bars represent quantitative analyses
of insulin-induced AKTSer473 phosphorylation/AKT OD ratio,
expressed as percentage of that observed in insulin-stimulated GFP
cells (white bars) at T0 (n= 3), T9 (n= 3) and T15 (n= 6). All data are
means ± SE. *2 sided p < 0.05 by Student’s t-test. A representative blot
for each experimental condition is shown
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[27–29], is paralleled and may be, therefore, at least partly
explained by the strikingly increased levels of resistin gene
(Retn) [30] observed during adipogenesis in GALNT2 over-
expressing cells.
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The insulin resistant phenotype we observed in GALNT2
mature adipocytes might be also explained by ceramides-
dependent mechanisms, known to inhibit insulin signaling,
through the PKR/JNK pathway [31]. However, although we
do acknowledge that lack of ceramides data is a limitation
of our study, data showing no changes between GFP and
GALNT2 cells in insulin-induced JNK phosphorylation,
make unlikely that ceramides-dependent mechanisms are
involved in reducing insulin signaling in GALNT2 mature
adipocytes.
In addition, it cannot be excluded that GALNT2 affects
adipogenesis also independently of insulin signaling. For
example, the coordinated change in the expression of key
maturation genes we observed along the whole course of
adipogenesis may have also played a role in mediating
GALNT2 promoted adipocyte enlargement. In fact, the
expression of some genes that are either up-regulated (Adig,
Retn, Nr1h3) or down-regulated (Ucp1, Slc2a4, Lipe, Fgf2,
Tcs22d3) in GALNT2 cells, has been previously reported to
associate with adipocytes lipid storage [32] and adiposity
measures [33–39], toward a coherent direction with our
present findings.
GALNT2 is involved in O-glycosylation (i.e., the
sequential addition of different monosaccharides to pro-
teins) an intracellular processing step of utmost importance
[40]. This also may have played a role in mediating
GALNT2 effect on adipogenesis. At this regard, increased
GALNT2 downstream glycosylation processes up-regulate
CEBPa and AdipoQ [41], whose expression was in fact
increased during adipocytes maturation in GALNT2 cells.
Finally, no matter the mechanisms mediating its effects
on adipogenesis, our finding envisions GALNT2 as an
attractive drug-target for tackling increased expansion of
adipose tissue and, therefore, the worldwide epidemic of
obesity and related dramatic sequelae. In fact, both gene
silencing and binding prevention tools are novel strategies
hoped to pave the way for inventing new treatments in the
field of metabolic diseases [42, 43]. Conversely, since
thiazolinediones have been proposed for treating lipody-
strophies of any origin [5, 44, 45], and since our data show
that the magnitude of GALNT2 stimulatory effect on adi-
pogenesis is similar to that of rosiglitazone, one could also
speculate that GALNT2 up-regulation might be a rational
approach for treating these conditions.
In conclusion, our data indicate that GALNT2 is a
positive modulator of adipocytes insulin signaling and point
it as a novel promoter of adipogenesis which eventually
causes adipocytes enlargement. Further studies are needed
to get deeper insights on the precise mechanisms by which
GALNT2 exerts its effects on adipocyte biology and to
address whether it may become a new target for treating
states of abnormal expansion of adipose tissue.
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